Product liability is one of the fastest growing and most economically significant applications of tort law. Product liability actions against pharmaceutical companies are among the most widely publicized classes of suits in the United States and Europe, prompting pharmaceutical companies to lobby vigorously for tort reform. (Nace et al., 1997). The liability burden on pharmaceutical companies h...

The Data mining is gradually becoming an integral and essential part of health and pharmaceutical industry. Data mining techniques are being regularly used to assess efficacy of treatment, management of ailments, and also in various stages of drug discovery and process research. Off late, data mining has become a boon in health insurance sector to minimize frauds and abuse. A good number of hea...

Funding combination is the most important issue for the companies while they know the amount of required capital. Companies should be careful regarding the appliance of financial providing methods compatible with the investment strategy of company and profitability. This study seeks to examine the relationship between the capital structure and the profitability of pharmaceutical companies in Ir...

Three recent systematic reviews have shown that pharmaceutical industry funding of clinical trials is strongly associated with pro-industry results. This article builds on those analyses, situating funding's effects in the context of the ghost-management of research and publication by pharmaceutical companies, and the creation of social ties between those companies and researchers. There are mu...

Goods, information, financial and technology resources flow through supply chains, and pharmaceutical companies face a very specific challenge: ethical drugs must be prescribed by physicians to be bought or used by final consumers. That gives a unique design to their supply chains. This paper aims to understand how the supply chains of pharmaceutical companies are configured. It especially expl...

According to the Egyptian Ministry of Health, the per capita use of prescription drugs in Egypt is amongst the highest in the world. Multinational pharmaceutical companies license their proprietary products for manufacture and sale in Egypt through their Egyptian subsidiaries. A Ministry of Health Committee reviews and approves for sale all drugs marketed in the country. Aside from being an ext...

Non-clinical animal studies to assess the safety of compounds under development have to comply with Good Laboratory Practice (GLP). The Organization for Economic Co-operation and Development (OECD) has established the Mutual Acceptance of Data (MAD) system in OECD member countries for the mutual acceptance of non-clinical safety study data. Since 1997 non-OECD-member countries have also been ab...

Drug regulators in Canada and in other nations require innovative pharmaceutical companies to submit undisclosed clinical or other data as a condition of approving the marketing of new pharmaceutical products-the origination of which involves considerable effort and investment. Data protection regulations were enacted in Canada in 2006, which-to some extent-closed a loophole in intellectual pro...

Regarding to rapidly changing and highly competitive business environment it will become increasingly important for organizations to measure their performances appropriately. With respect to special characteristics of pharmaceutical industry and lack of reported performance measurement, this study tries to design an integrated performance measurement model for pharmaceutical companies. For gene...